View Older Stories View More Recent Stories

Mar 22, 2022 10:39AM H.C. Wainwright Reiterates Nuvectis Pharma (NVCT) at Buy with $14 PT, Sees 85% Probability of Success for NXP800

Mar 22, 2022 10:33AM BMO Capital Reiterates Vertex (VRTX) at Outperform with $274 Price Target, Sees Good Odds of Proteinuria-based Approval of VX-147

Mar 22, 2022 10:12AM Dawson James Reiterates Neutral Rating on Adamis Pharmaceuticals (ADMP)

Mar 22, 2022 09:51AM Truist Securities Reiterates argenx SE (ARGX) at Buy with $365PT, Sees SC-efgart "Approvable" on Trial Results, Notes Room for Possible Label Expansion

Mar 22, 2022 09:06AM Truist Securities Reiterates Vertex (VRTX) at Buy, $341 PT, Sees VX-147 Advancements as Positive Step for VRTX's Diversification, Models Peak Sales of $1B

Mar 22, 2022 08:44AM Raymond James Reiterates argenx SE (ARGX) at Strong Buy, Sees New Data Unlocking Additional Value

Mar 22, 2022 06:42AM Oppenheimer Reiterates Caribou Biosciences (CRBU) at Outperform with $36 PT

Mar 22, 2022 06:39AM Nuvation Bio Inc (NUVB) PT Lowered to $12 at BMO Capital on Lower Assumed Penetration Rates, but Optimistic Reiterated Ahead of Phase 1 NUV-422 Readout

Mar 22, 2022 06:28AM Needham & Company Reiterates Revance Therapeutic (RVNC) at Buy with $25 PT, New Financing is a Positive Development

Mar 21, 2022 12:18PM Cowen Reiterates Marinus Pharmaceuticals (MRNS) at Outperform Following Ztalmy Approval

Mar 21, 2022 12:06PM Brookline Capital Markets Reiterates SQZ Biotechnologies (SQZ) at Buy with $42 PT, Grant Announcement is Very Supportive of SQZ's Potential

Mar 21, 2022 09:15AM Brookline Capital Markets Reiterates Moderna (MRNA) at Buy, $506 PT, Sees Sales of 1.18B Vaccine Doses in 2022

Mar 21, 2022 09:13AM Dawson James Reiterates Dyadic International (DYAI) at Buy, $6 PT, Sees 20% Probability of Success of C1 Platform

Mar 21, 2022 06:04AM Truist Securities Reiterates Marinus Pharmaceuticals (MRNS) at Buy, $35 PT, ZTALMY Approval was Expected but Still a Relief, Sees $200M Peak Sales but a Much Larger Opportunity in Ongoing TSC Trial

Mar 18, 2022 09:48AM Dawson James Reiterates Kintara Therapeutics (KTRA) at Buy, $5 PT

Mar 18, 2022 08:56AM Crown Electrokinetics (CRKN) PT Slashed to $4.25 ad Dawson James, but Buy Rating Maintained, Analyst Sees $100M of Revenue in 5-7 Years

Mar 18, 2022 06:55AM Oppenheimer Reiterates Outperform Rating, $7 PT on Synlogic Inc. (SYBX)

Mar 18, 2022 06:09AM Truist Securities Reiterates Buy Rating, $12 PT on Catalyst Pharmaceutical Partners (CPRX)

Mar 18, 2022 06:07AM Needham & Company Reiterates Buy Rating, $8 PT on Trevi Therapeutics (TRVI) Ahead of PRISM Trial Readout

Mar 18, 2022 06:03AM Replimune Group (REPL) PT Lowered to $30 at BMO Capital, but Analyst Remains Optimistic on Shares Ahead of Near Term Catalysts

Mar 17, 2022 04:34PM Avrobio Inc. (AVRO) PT Lowered to $2 at Stifel

Mar 17, 2022 12:24PM Needham & Company Reiterates Buy Rating, $12 PT on Liquidia Technologies (LQDA) on Yutrepia Potential

Mar 17, 2022 10:55AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) Overwight, $10 PT, Sees Company's Bromodomain and Extra-Terminal Domain Inhibitors Programs are Underappreciated

Mar 17, 2022 10:35AM Avadel Pharmaceuticals (AVDL) PT Lowered to $13 at Stifel, but Maintained at Buy, Analyst Sees Latest FT218 Commentary as Good News and Expects Near Term Approval

Mar 17, 2022 10:14AM Needham & Company Reiterates Avrobio (AVRO) at Outperform, $8 PT, Remains Supporter of Company's LV Based Gene Therapy Programs

Mar 17, 2022 09:46AM Dawson James Reiterates Buy Rating on OncoSec Medical (ONCS)

Mar 17, 2022 06:10AM Mizuho Securities Reiterates eFFECTOR Therapeutics (EFTR) a Buy, $20 PT, but Sees Low Cash as Overhang on Shares

Mar 16, 2022 07:15PM eFFECTOR Therapeutics, Inc. (EFTR) PT Lowered to $4 at Stifel, Analyst Reiterates Hold, Awaits Proof-of-Concept tomivosertib Data

Mar 16, 2022 07:12PM Cantor Fitzgerald Reiterates eFFECTOR Therapeutics (EFTR) at Overweight, $50 PT, "Company's Pipeline Remains Underappreciated", Expect Advancements to Move Stock Higher

Mar 16, 2022 07:10PM Mizuho Securities Reiterates Satsuma Pharmaceuticals (STSA) at Buy, $15 PT, Remains Bullish on STS101's Potential

Mar 16, 2022 04:29PM Needham & Company Reiterates Buy Rating on Inozyme Pharma Inc. (INZY)

Mar 16, 2022 04:26PM Stifel Reiterates ChemoCentryx (CCXI) at Buy, $85 PT, but Warns of Potential Slower Uptake of Tavneos

Mar 16, 2022 01:27PM Needham & Company Reiterates Apellis Pharmaceuticals (APLS) at Buy, $70 PT, "Data Bode Well for Approval in GA"

Mar 16, 2022 12:08PM Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA) on Japan's Vaccine Order

Mar 16, 2022 09:25AM Dawson James Reiterates Buy Rating, $7 PT on Athersys (ATHX), Sees Company as Undervalued Upon Success of Clinical Trials

Mar 16, 2022 06:34AM Oppenheimer Reiterates Outperform Rating on Brickell Biotech (BBI)

Mar 16, 2022 06:33AM Oppenheimer Reiterates Outperform Rating on Syros Pharmaceuticals (SYRS), Sees Relatively Low Clinical Risk for SY-2101

Mar 16, 2022 06:22AM Precision BioSciences Inc. (DTIL) PT Lowered to $16 at Stifel, Maintained at Buy, Analyst Remains Bullish into Expected CD19-CAR-T Data

Mar 16, 2022 06:18AM Oppenheimer Reiterates Gamida Cell (GMDA) at Outperform, $15 PT, Sees Potential omidubicel Approval in 1H23

Mar 16, 2022 06:16AM Needham & Company Reiterates Athersys (ATHX) at Buy, TREASURE Study Remains Key Catalyst, but Limited Cash Poses Significant Overhang

Mar 16, 2022 06:14AM Mizuho Securities Reiterates Xeris Pharmaceuticals (XERS), Lowers PT to $6

Mar 16, 2022 06:06AM Oppenheimer Reiterates Opiant Pharma (OPNT) at Outperform Following Earnings

Mar 15, 2022 02:59PM Ideaya Biosciences (IDYA) PT Lowered to $17 at Stifel on "Mixed" IDE397 Data, but Sees $10 as Floor Value of Stock

Mar 15, 2022 11:19AM William Blair Reiterates Brickell Biotech (BBI) at Outperform, Sees "Strong Risk/Reward Profile" at Current Valuations

Mar 15, 2022 11:17AM Needham & Company Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)

Mar 15, 2022 10:01AM Stifel Maintains Alector (ALEC) at Hold, New Data is Intriguing but with Important Caveats

Mar 15, 2022 06:08AM BMO Capital Reiterates Biogen (BIIB) at Outperform, Eisai Sees More Value in lecanemab Than Aduhelm

Mar 14, 2022 04:04PM Needham & Company Reiterates Buy Rating on Mereo BipPharma Group (MREO)

Mar 14, 2022 02:15PM Raymond James Reiterates Outperform Rating on BridgeBio Pharma (BBIO)

Mar 14, 2022 10:01AM Needham & Company Reiterates Liquidia Technologies (LQDA) at Buy, Continues to Expect Full Approval of Yutrepia

View More Recent Stories View Older Stories